Combined transarterial chemoembolization and tislelizumab for patients with unresectable hepatocellular carcinoma

Table 1 Characteristics of the patients

Characteristics	Values
Age (years), median (P25-P75)	53 (47.5-58)
< 60, n (%)	49 (87.50)
≥ 60, n (%)	7 (12.50)
Sex, n (%)
Male	50 (89.29)
Female	6 (10.71)
Viral infection, n (%)
Hepatitis B virus	42 (75.00)
Hepatitis C virus	3 (5.36)
Hepatitis B and C viruses	11 (19.64)
Prior cancer treatment modalities, n (%)
Untreated	24 (42.86)
Surgery	6 (10.71)
Ablation therapy	3 (5.36)
TACE	23 (41.07)
Line of immunotherapy, n (%)
First-line	49 (87.5.0)
Second-line	5 (8.93)
Third-line and beyond	2 (3.57)
Immunotherapy cycles	4 (3-8.5)
≤ 4 cycles	29 (51.79)
> 4 cycles	27 (48.21)
TACE sessions, median (P25-P75)	1 (1-2)
1 time, n (%)	36 (64.29)
2 times, n (%)	13 (23.21)
3 times or more, n (%)	7 (12.50)
Immunotherapy sequence, n (%)
Before	21 (37.50)
After	35 (62.50)
Concomitant targeted/immunotherapy, n (%)
No	5 (8.93)
Yes	51 (91.07)
Targeted/immunotherapy agents, n (%)
Lenvatinib	36 (64.29)
Apatinib	3 (5.36)
Bevacizumab	3 (5.36)
Regorafenib	6 (10.71)
Sorafenib	3 (5.36)
Targeted therapy duration (months), median (P25-P75)	5 (3-9)
Tumor maximum diameter (mm), median (P25-P75)	65 (39-93.5)
Tumor distribution, n (%)
Unilateral liver	34 (60.71)
Bilateral liver	22 (39.29)
Vascular invasion, n (%)	21 (37.50)
Extrahepatic metastasis, n (%)	7 (12.50)
BCLC staging, n (%)
A	4 (7.14)
B	16 (28.57)
C	36 (64.29)
Child-Pugh score, n (%)
A	55 (98.21)
B	1 (1.79)
ECOG performance status, n (%)
0	54 (96.43)
1	2 (3.57)
AFP (ng/mL), median (P25-P75)	227.29 (38.7-9484.5)
ALT (IU/L), median (P25-P75)	38.9 (26.25-60.7)
AST (IU/L), median (P25-P75)	46 (34.25-76.2)
Total bilirubin (µmol/L), median (P25-P75)	16.4 (12.65-23.025)

TACE: Transarterial chemoembolization; BCLC: Barcelona Clinic Liver Cancer; ECOG: Eastern Cooperative Oncology Group; AFP: Α-fetoprotein; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase.